Urokinase is mainly used in thrombolytic therapy for thromboembolic
diseases. Patients with acute generalized pulmonary embolism, coronary artery
embolization and myocardial infarction within 6 to 12 hours of chest pain, acute
cerebral vascular embolization with symptoms less than 3 to 6 hours, retinal
artery embolization and other peripheral arterial embolization with severe
ilio-femoral vein thrombosis were included. It is also used to prevent
thrombosis after artificial heart valve operation, maintain the vascular
intubation and unobstructed thoracic and pericardial drainage tube, etc. The
effect of thrombolysis needs to be maintained by subsequent heparin
anticoagulation.
This product is contraindicated in patients with the following conditions:
acute visceral hemorrhage, acute intracranial hemorrhage, old cerebral
infarction, intracranial or spinal surgery performed within the last two months,
intracranial tumor, arteriovenous malformation or aneurysm, bleeding diathesis,
and severe uncontrolled hypertension. Relative contraindication includes
prolonged cardiopulmonary resuscitation, severe hypertension, trauma within
nearly 4 weeks, surgery or tissue puncture within 3 weeks, pregnancy, 10 days
after delivery, active ulcer disease.
Above is urokinase related introduction, if needs to learn more please
continue to follow kang Yuan website.